Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 1 - 20 out of 500 displayed.
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
Reset 

Phillips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards

Read more ››
By: Nasdaq / GlobenewsWire - 24 Jun 2018

Thermo Fisher Scientific Donates Rapid DNA Analysis Technology to Help Reunite Families Recently Separated at Border

WALTHAM, Mass., June 24, 2018 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it is offering to donate $1 million worth of rapid DNA analyzers and related technology to support efforts to reunite children and parents recently separated... Read more ››

By: PR Newswire Association LLC. - 24 Jun 2018
Related companies:  Thermo Fisher Scientific Inc.

Adding Liraglutide to Insulin Regimen for People with Type 1 Diabetes Improved Glycemic Control

ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- Adults with type 1 diabetes (T1D) who take a daily dose of liraglutide demonstrated improvements in HbA1c levels, weekly average blood glucose levels and increased weight loss, according to the study, "Liraglutide as an Additional Treatment... Read more ››

By: PR Newswire Association LLC. - 24 Jun 2018
Related companies:  American Diabetes Association

Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW

INDIANAPOLIS, June 24, 2018 /PRNewswire/ -- People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on treatment longer with once-weekly Trulicity(®) (dulaglutide)... Read more ››

By: PR Newswire Association LLC. - 24 Jun 2018
Related companies:  Eli Lilly and Company

Intense Multifactorial Treatment for Type 2 Diabetes Shown to be Cost Effective

ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- When patients with type 2 diabetes (T2D) receive intensified, multifactorial treatment combining lifestyle modification and pharmacological therapy for modifiable risk factors, there is no significant increase in medical costs, compared... Read more ››

By: PR Newswire Association LLC. - 24 Jun 2018
Related companies:  American Diabetes Association

MIM Software Inc. Partners with Spectrum Dynamics Medical

CLEVELAND, June 24, 2018 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imaging and Nuclear Medicine software, announced today it has partnered with Spectrum Dynamics Medical (Israel) to provide MIM-SD, an advanced visualization and quantitative processing software for... Read more ››

By: PR Newswire Association LLC. - 24 Jun 2018

Alirocumab and Statins Highly Effective in People with Diabetes with Acute Coronary Syndrome

ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- People with diabetes who have experienced recent acute coronary syndrome (ACS) and take a combination of alirocumab and statins may reduce their risk of future cardiac events by more than double that of people on the same medication regimen... Read more ››

By: PR Newswire Association LLC. - 24 Jun 2018
Related companies:  American Diabetes Association

Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications

TITUSVILLE, N.J. and ORLANDO, Fla., June 24, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced late-breaking results of a new real-world analysis of more than 700,000 U.S. T2D patients, which found no increased risk of below-knee lower extremity... Read more ››

By: PR Newswire Association LLC. - 24 Jun 2018

Real World Study Suggests Canagliflozin Does Not Increase Risk of Below-Knee Amputation in People with Type 2 Diabetes

ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- Canagliflozin does not increase the risk of amputation for the general type 2 diabetes (T2D) population or in patients with established cardiovascular disease, but does reduce a patient's risk of hospitalization for heart failure, according... Read more ››

By: PR Newswire Association LLC. - 24 Jun 2018
Related companies:  American Diabetes Association

Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018

Tresiba® demonstrated significantly lower A1C and rates of hypoglycaemia versus insulin glargine U-300 in real-world evidence study

ORLANDO, Fla., June 23, 2018 /PRNewswire/ -- Findings from CONFIRM - a large, retrospective real-world evidence (RWE) study comparing the effectiveness of Tresiba(®) (insulin degludec injection) 100 U/mL, 200 U/mL versus insulin glargine U-300 in more than 4,000 adults with type 2 diabetes who... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Novo Nordisk Inc.

Omnipod® Hybrid Closed-Loop Insulin Delivery System Significantly Improves Glycemic Control in Adults with Type 1 Diabetes

ORLANDO, Fla., June 23, 2018 /PRNewswire-USNewswire/ -- Adults with type 1 diabetes using the Omnipod hybrid closed-loop system (the Horizon(TM) Automated Glucose Control System) were studied in a supervised outpatient hotel setting with unrestricted meals and moderate-intensity exercise and... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  American Diabetes Association

Dual-Hormone, Artificial Pancreas with Insulin and Pramlintide Significantly Improves Glucose Levels, Compared to Insulin-Only Artificial Pancreas

ORLANDO, Fla., June 23, 2018 /PRNewswire-USNewswire/ -- A dual-hormone, artificial pancreas(1) delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an insulin-only, first-generation artificial... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  American Diabetes Association

Fully Implantable, Continuous Glucose Monitoring Sensor Provided Accuracy for Six Months in Adolescents and Adults with Type 1 Diabetes

ORLANDO, Fla., June 23, 2018 /PRNewswire-USNewswire/ -- When adolescents and adults with type 1 diabetes (T1D) used a new continuous glucose monitoring (CGM) device containing a sensor that can remain implanted in the arm for up to 180 days, the system provided accurate glucose measurement with... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  American Diabetes Association

Diabeloop Insulin Delivery System May Significantly Improve Glycemic Control for People with Type 1 Diabetes

ORLANDO, Fla., June 23, 2018 /PRNewswire-USNewswire/ -- New research finds that people with type 1 diabetes (T1D) who used the Diabeloop DBLG1 therapeutic, closed-loop insulin delivery system in a home setting experienced a greater percentage of time in the target blood glucose range and fewer... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  American Diabetes Association

One Drop Announces Blood Glucose Prediction and Automated Decision Support

NEW YORK, June 23, 2018 /PRNewswire/ -- One Drop, a leader in the development of digital therapeutics solutions for people with diabetes, today announced the launch of Blood Glucose Prediction and Automated Decision Support. Through these new features, the One Drop | Mobile app will provide users:... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018

BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018

Significant blood sugar improvement with Xultophy® compared to insulin glargine U-100 when used as add-on to oral diabetes medications

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018

Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018

Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
to the top ↑